4.5 Review

Nanoparticle Delivery Systems in Cancer Vaccines

Journal

PHARMACEUTICAL RESEARCH
Volume 28, Issue 2, Pages 215-236

Publisher

SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s11095-010-0241-4

Keywords

cancer immunotherapy; colloidal nanocarriers; liposomes; polymeric nanoparticles; tumor targeting

Funding

  1. American Cancer Society [RSG-09-015-01-CDD]
  2. National Cancer Institute at the National Institutes of Health [1R21CA13345-01/1R21CA128414-01A2]
  3. Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation
  4. Guillory Fellowship

Ask authors/readers for more resources

Therapeutic strategies that involve the manipulation of the host's immune system are gaining momentum in cancer research. Antigen-loaded nanocarriers are capable of being actively taken up by antigen-presenting cells (APCs) and have shown promising potential in cancer immunotherapy by initiating a strong immunostimulatory cascade that results in potent antigen-specific immune responses against the cancer. Such carrier systems offer versatility in that they can simultaneously co-deliver adjuvants with the antigens to enhance APC activation and maturation. Furthermore, modifying the surface properties of these nanocarriers affords active targeting properties to APCs and/or enhanced accumulation in solid tumors. Here, we review some recent advances in these colloidal and particulate nanoscale systems designed for cancer immunotherapy and the potential for these systems to translate into clinical cancer vaccines.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available